Calliditas Therapeutics AB (FRA:LC8)
€ 17.83 0.06 (0.34%) Market Cap: 963.42 Mil Enterprise Value: 981.96 Mil PE Ratio: 0 PB Ratio: 104.30 GF Score: 51/100

Calliditas Therapeutics AB (publ) - Special Call Transcript

Mar 10, 2021 / 03:00PM GMT
Release Date Price: €11.94 (+2.75%)
Operator

Good morning, and welcome to the Calliditas Therapeutics Expert Perspectives Webinar. (Operator Instructions)

As a reminder, today's event is being recorded and a replay will be made available on the Calliditas' website.

I would now like to turn the call over to your host, Ashley Robinson of LifeSci Advisors. Please go ahead, sir.

Ashley R. Robinson
LifeSci Advisors, LLC - MD

Thank you, Sarah, and good morning, and good afternoon, everyone, and thank you for joining us today for the Calliditas Therapeutics key opinion leader perspective webinar on the pathophysiology and treatment of IgA nephropathy in clinical practice. My name is Ashley Robinson from Lifesci Advisors, and I would be introducing the event as well as moderating the question-and-answer session.

As you know, Calliditas is a specialty pharmaceutical company, listed in Stockholm, Sweden, and in the U.S. on NASDAQ. It is focused on identifying, developing and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot